Trevi Therapeutics, INC Schedule 13G passive stakes

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 8.8% of Trevi Therapeutics Inc.'s common stock as of June 30, 2026.

FMR LLC and Abigail P. Johnson have reported a combined beneficial ownership of 6.3% of Trevi Therapeutics Inc.'s common stock as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in Trevi Therapeutics Inc. due to an internal realignment.

Rubric Capital Management LP and David Rosen have reported a reduced beneficial ownership stake of 2.94% in Trevi Therapeutics, Inc. as of December 31, 2025.

FMR LLC and Abigail P. Johnson have reported a 5.1% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

The Vanguard Group reported a 5.01% beneficial ownership stake in Trevi Therapeutics Inc. common stock as of December 31, 2025.

Viking Global Investors LP and its affiliates have filed an amended Schedule 13G, disclosing a 4.2% beneficial ownership stake in Trevi Therapeutics, Inc. as of September 30, 2025.

Frazier Life Sciences Public Fund and affiliates updated their beneficial ownership in Trevi Therapeutics, reporting a combined 7.0% stake.

BlackRock, Inc. has reported a 5.6% beneficial ownership stake in Trevi Therapeutics, Inc., holding 6,804,338 shares of common stock as of September 30, 2025.

Viking Global Investors LP and its affiliates reported a beneficial ownership of 5.9% in Trevi Therapeutics, Inc., including common stock and pre-funded warrants.

Rubric Capital Management LP and David Rosen have jointly disclosed a beneficial ownership of 7.12% of Trevi Therapeutics, Inc.'s common stock, totaling 8,531,860 shares.

Viking Global Investors LP and its affiliates have reported an 8.7% beneficial ownership stake in Trevi Therapeutics, Inc., as detailed in a recent Schedule 13G filing with the SEC.

Frazier Life Sciences Public Fund, L.P. and affiliated entities, along with key individuals, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 10.6% in Trevi Therapeutics, Inc.

Venrock Healthcare Capital Partners and its affiliated entities have filed an amended Schedule 13G, disclosing a 1.4% beneficial ownership stake in Trevi Therapeutics, Inc. as of December 31, 2024.

Frazier Life Sciences and affiliated entities have filed an amended Schedule 13G/A, reaffirming their passive beneficial ownership in Trevi Therapeutics, Inc. as of December 31, 2024.

Rubric Capital Management LP and David Rosen have filed an amended Schedule 13G, reporting a 4.71% beneficial ownership stake in Trevi Therapeutics, Inc. as of December 31, 2024.

Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals have filed an amendment to their Schedule 13G, disclosing a passive beneficial ownership of 1.21% in Trevi Therapeutics, Inc.'s common shares.